Compare Novavax Inc (NVAX) vs Invesco S&P 500 Momentum ETF (SPMO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novavax Inc vs Invesco S&P 500 Momentum ETF — how do they compare? Novavax Inc trades at $11.75 (market cap $1.82B), while Invesco S&P 500 Momentum ETF trades at $151.84 (market cap $23.48B). The key difference: Invesco S&P 500 Momentum ETF is far larger — about 12.9× Novavax Inc's market cap, and Novavax Inc is more actively traded (6,198,505 versus 1,876,152). Which is the better fit depends on your goals — on Pluang, investors hold Novavax Inc for 59 Days and Invesco S&P 500 Momentum ETF for 54 Days on average.
| NVAX | SPMO | |
|---|---|---|
Market Cap | $1.82B | $23.48B |
Volume | 6,198,505 | 1,876,152 |
Sector | Health | Broad Market / Factor |
52-Week High | $12.56 | $161.66 |
52-Week Low | $6.22 | $107.84 |
Typical Hold Time | 59 Days | 54 Days |
Enterprise Value | $1.39B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novavax (NVAX) trades at $11.22, down 0.88% on the day, with a bullish technical signal from moving averages and a neutral RSI. The company reported strong revenue of $1.12 billion in 2025 and a net income of $440.30 million, but faces negative cash flow and a projected net loss for 2026. Recent news highlights its strategic pivot to a partnership-driven model using its Matrix-M adjuvant technology, with regulatory approvals for its updated COVID-19 vaccine in key markets.
The outlook for NVAX is mixed, with analyst consensus strongly favoring a buy rating (73.92%) but significant financial risks including negative equity, persistent cash burn, and volatile earnings. Investment opportunity lies in the successful execution of its licensing strategy and expansion into oncology, though execution risks and competitive pressures remain key concerns for shareholders.
SPMO trades at $153.00, showing minimal daily movement with a 0.01% gain. The ETF maintains a bullish technical outlook with strong moving average signals, though oscillators suggest neutral momentum. Recent portfolio reconstitution added 54 stocks including Apple and Merck, while removing Nvidia. Institutional interest remains strong with Envestnet Asset Management increasing its stake by 9.5% in Q2 2026.
The momentum-focused ETF offers concentrated exposure to S&P 500's fastest-rising stocks, historically outperforming the broader index. Key risks include sector concentration in technology and higher volatility. Analyst sentiment remains positive given the fund's structural momentum advantage and institutional accumulation trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →About Invesco S&P 500 Momentum ETF
SPMO is designed to track the investment results of the S&P 500 Momentum Index. This index measures the performance of stocks in the S&P 500 that exhibit the highest momentum, or the greatest price appreciation, over the trailing 12 months, while excluding the most recent month. By investing in these high-momentum stocks, SPMO seeks to capitalize on the historical trend that stocks with strong recent performance tend to continue that performance in the near term, offering a systematic approach to factor investing within the large-cap U.S. equity market.
Read more on SPMO →
